GnRH激动剂触发在计划性卵母细胞冷冻中的成熟率研究
总体平均成熟率为0.71±0.19,GnRH激动剂触发亚组为0.73±0.18;峰值雌二醇>3000 pg/mL与<3000 pg/mL组间成熟率无显著差异(0.72±0.19 vs 0.74±0.14,P=0.18)。
要点
- GnRH激动剂触发适用于计划性卵母细胞冷冻,无论卵巢反应如何。
- 峰值雌二醇>3000与<3000 pg/mL组成熟率无显著差异(P=0.18)。
- 雌二醇<1000 pg/mL周期成熟率较低,与触发类型无关。
核心结论
- GnRH激动剂是计划性卵母细胞冷冻中卵母细胞最终成熟的合适选择,与刺激反应或OHSS风险无关。
主要发现
- 总体平均成熟率为0.71±0.19,GnRH激动剂触发亚组为0.73±0.18。
- 611个周期(63.7%)峰值雌二醇<3000 pg/mL,331个(34.5%)>3000 pg/mL。
- 峰值雌二醇>3000与<3000 pg/mL组成熟率无显著差异(0.72±0.19 vs 0.74±0.14,P=0.18)。
- 较低峰值雌二醇与较低平均获卵数和平均MII卵数相关,但各雌二醇水平组间成熟率无显著差异。
- 雌二醇<1000 pg/mL周期成熟率较低,与触发类型无关。
关键数值与推荐
- 样本量计算:90%把握度、5%显著性、非劣效界值<0.05(以0.75成熟率为参照),每组需至少116个周期。
临床怎么用
- 在计划性卵母细胞冷冻中可考虑使用GnRH激动剂触发,包括正常和低反应者。
- 雌二醇<1000 pg/mL的周期成熟率较低,需予以关注。
局限性
- 回顾性设计不能完全排除选择偏倚、混杂因素或电子病历未采集的变量。
- 计划性卵母细胞冷冻的持续妊娠率和出生结局研究自然滞后。
- 研究人群限于计划性卵母细胞冷冻女性,结果可能不适用于IVF人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Does GnRH-agonist trigger offer similar maturity rate (MR) in low and normal responders compared to high responders in women undergoing planned oocyte cryopreservation, for whom even a small risk of ovarian hyperstimulation syndrome (OHSS) may not be acceptable? SUMMARY ANSWER: GnRH-agonist is an appropriate choice for final maturation of oocytes in planned oocyte cryopreservation, regardless of response to stimulation or risk of ovarian hyperstimulation syndrome. WHAT IS KNOWN ALREADY: Numerous studies have demonstrated the utility of GnRH-agonist trigger for the prevention of ovarian hyperstimulation in high-responder in vitro fertilization cycles. Limited data exist supporting its use in normal or low responders, or in non-infertile women undergoing planned oocyte cryopreservation. STUDY DESIGN, SIZE, DURATION: Retrospective cohort study of 1189 subjects including all planned oocyte cryopreservation cycles performed at a large, single center, oocyte cryopreservation program from April 2016 to December 2018. PARTICIPANTS/MATERIALS, SETTING, METHODS: A total of 1680 cycles were included in the study. A total of 57.1% (959/1680) utilized GnRH-agonist for trigger. Demographic and clinical data were collected from the medical record. Maturation rate was calculated for the entire cohort, and by trigger type, using the quotient of Metaphase II (MII) oocytes and retrieved oocytes. A sub-cohort of GnRH-agonist trigger cycles were categorized by peak estradiol (E2) levels and maturation rates compared between groups. Associations were made using Student's t test, ANOVA, Mann-Whitney U and Kruskal-Wallis, where appropriate. A sample size calculation for 90% power with a significance of 5% to detect non-inferiority of <0.05 from a 0.75 maturity rate between subjects with E2 > 3000 pg/mL and E2 < 3000 pg/mL demonstrated the need for at least 116 cycles per group. MAIN RESULTS AND THE ROLE OF CHANCE: Mean MR was 0.71 ± 0.19 overall, and 0.73 ± 0.18 in the sub-cohort of GnRH-agonist trigger cycles. A total of 611 cycles (63.7%) had peak E2 < 3000, and 331 (34.5%) had E2 > 3000. No significant difference in maturity rate was noted between cycles with E2 levels >3000 pg/mL and <3000 pg/mL (0.72 ± 0.19 vs. 0.74 ± 0.14, P = 0.18), confirming the non-inferiority of maturity rates with GnRH-agonist triggers in cycles with peak E2 < 3000 pg/mL. While lower mean oocytes retrieved and mean MII oocytes were associated with lower peak E2 levels, maturity rate did not significantly differ amongst E2 level groups. Cycles with E2 < 1000 pg/mL had lower MR irrespective of trigger type. LIMITATIONS, REASONS FOR CAUTION: The retrospective nature cannot entirely exclude selection biases, confounding factors or additional variables that could not be accounted for or were not collected by the electronic medical record. Given the nature of planned oocyte cryopreservation, studies of ongoing pregnancy rates and birth outcomes will naturally be delayed. Lastly, the study population was limited to women undergoing planned oocyte cryopreservation; therefore, the results may not be generalizable to women undergoing in vitro fertilization. WIDER IMPLICATIONS OF THE FINDINGS: This is the first study specifically comparing the efficacy of GnRH-agonist in patients at lower risk for OHSS to those at high risk, as well the first study evaluating GnRH-agonist's efficacy specifically in planned oocyte cryopreservation cycles. STUDY FUNDING/COMPETING INTEREST(S): Study support provided by departmental funds from the Center for Fertility Research and Education-Extend Fertility Medical Practice. BLM discloses personal fees from Ferring Pharmaceuticals and Merck KgAA, unrelated to the submitted work. C.S., M.G., L.R. and J.K. have nothing to disclose. TRIAL REGISTRATION NUMBER: N/A.
引用
- Maslow BL, Guarnaccia M, Stefanacci C, et al. The use of GnRH-agonist trigger for the final maturation of oocytes in normal and low responders undergoing planned oocyte cryopreservation. Hum Reprod. 2020. PMID: 32406915. doi:10.1093/humrep/deaa042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。